MORRISTOWN, N.J., June 26, 2012 /PRNewswire/ --Fertility experts at Reproductive Medicine Associates of New Jersey (RMANJ) announced that they will partner with Auxogyn, Inc., to conduct a groundbreaking IVF study that aims to advance the goals of single embryo transfer (SET), and reduce the financial and health implications of multiple pregnancies. (Logo: http://photos.prnewswire.com/prnh/20120402/NY80340LOGO) "Our objectives at RMANJ are two-fold: To increase the healthy live birth rate for those undergoing assisted reproductive procedures, and to decrease the multiple embryo transfer rate, thereby reducing multiple pregnancies," commented Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D., founding partner of RMANJ. "Through this collaborative research study with Auxogyn, we will explore new, previously unidentified factors that cause one chromosomally normal embryo to implant where another seemingly healthy embryo does not. These discoveries could directly impact clinical practice in the future, moving us closer to the ultimate goal of the IVF field one embryo, one healthy baby." For patients enrolled in the study, researchers will evaluate the use of both RMANJ's proprietary Comprehensive Chromosome Screening (CCS) and Auxogyn's Eeva (Early Embryo Viability Assessment) Test to detect healthy embryos prior to implantation. CCS is a rapid-method 24-chromosome screening technique that accurately identifies whether embryos are euploid (have … Continue reading →

MORRISTOWN, N.J., June 26, 2012 /PRNewswire/ --Fertility experts at Reproductive Medicine Associates of New Jersey (RMANJ) announced that they will partner with Auxogyn, Inc., to conduct a groundbreaking IVF study that aims to advance the goals of single embryo transfer (SET), and reduce the financial and health implications of multiple pregnancies. (Logo: http://photos.prnewswire.com/prnh/20120402/NY80340LOGO) "Our objectives at RMANJ are two-fold: To increase the healthy live birth rate for those undergoing assisted reproductive procedures, and to decrease the multiple embryo transfer rate, thereby reducing multiple pregnancies," commented Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D., founding partner of RMANJ. "Through this collaborative research study with Auxogyn, we will explore new, previously unidentified factors that cause one chromosomally normal embryo to implant where another seemingly healthy embryo does not. These discoveries could directly impact clinical practice in the future, moving us closer to the ultimate goal of the IVF field one embryo, one healthy baby." For patients enrolled in the study, researchers will evaluate the use of both RMANJ's proprietary Comprehensive Chromosome Screening (CCS) and Auxogyn's Eeva (Early Embryo Viability Assessment) Test to detect healthy embryos prior to implantation. CCS is a rapid-method 24-chromosome screening technique that accurately identifies whether embryos are euploid (have … Continue reading →

ScienceDaily (June 26, 2012) Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state. Now, in a unique study, a UCLA research team led by Thomas Graeber, a professor of molecular and medical pharmacology, has investigated the reverse aspect: how the metabolism of glucose affects the biochemical signals present in cancer cells. In research published June 26 in the journal Molecular Systems Biology, Graeber and his colleagues demonstrate that glucose starvation -- that is, depriving cancer cells of glucose -- activates a metabolic and signaling amplification loop that leads to cancer cell death as a result of the toxic accumulation of reactive oxygen species, the cell-damaging molecules and ions targeted by antioxidants like vitamin C. The research, which involved UCLA scientists from the Crump Institute for Molecular Imaging, the Institute for Molecular Medicine, the California NanoSystems Institute, the Jonsson Comprehensive Cancer Center, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and … Continue reading →

The Sugar Land company involved in Gov. Rick Perry's unlicensed adult stem-cell procedure is rife with basic manufacturing problems, according to the U.S. Food and Drug Administration. In a report one expert called a blow to the entire adult stem-cell industry, the FDA found that Celltex Therapeutics Corp. cannot guarantee the sterility, uniformity and integrity of stem cells it takes from people and then stores and grows for eventual therapeutic reinjection. "You have not performed a validation of your banking and thawing process to assure viability" of the stem cells, reads the April 27 report, meaning that the company cannot verify the cells are alive. The FDA report, which followed an April 16-27 inspection of Celltex, was released under the Freedom of Information Act Monday to the Houston Chronicle and a University of Minnesota bioethicist who complained in February that Celltex is a potential danger to patients and not in compliance with federal law. The report, partially redacted, was not accompanied by a warning letter. A former FDA official who asked not to be identified, however, said the deficiencies - 79 in all, from incorrectly labeled products to failed sterility tests - are so serious that Celltex risks being shut … Continue reading →